At a glance
ClinicalIndex Comparison Record- ✓Clinically Isolated Syndrome (CIS) or RRMS diagnosis
- ✓First DMT (treatment naïve) or second DMT of different drug class
- ✓Follow-up at Swedish university clinics
- ✓Capable of completing study assessments
- ✕Progressive forms of MS at start of therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
COMparison Between All immunoTherapies for Multiple Sclerosis. An Observational Long-term Prospective Cohort Study of Safety, Efficacy and Patient's Satisfaction of MS Disease Modulatory Treatments in Relapsing-remitting Multiple Sclerosis
In Brief
An observational study evaluating Rituximab for Relapsing-remitting Multiple Sclerosis. Completed, enrolled 3,526 participants across 1 site.
Detailed Summary
The overarching goal of this study is to determine whether rituximab (RTX) offers effectiveness and safety advantages over other commonly used approved Disease-Modifying Drugs (DMT) in the largest real-world population-based structured prospective follow-up cohort of Relapsing-Remitting Multiple Sclerosis (RRMS) patients. The study will include both treatment naïve patients starting their first DMT and patients switching from a previous first line DMT (escalation/second-line).
Study Details
Timeline
Interventions
Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis